Crohn's disease
Description
An in-depth report on the causes, diagnosis, treatment, and prevention of Crohn's disease.
Alternative Names
Inflammatory bowel disease - Crohn's disease
Highlights
Drug Approval
Adalimumab (Humira) was approved in 2007 to treat adults with moderate-to-severe Crohn's disease.
Infliximab (Remicade) was approved in 2006 for treating active Crohn’s disease in children. The drug was previously approved for adults with Crohn’s disease.
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
NSAIDS such as acetaminophen (Tylenol), naproxen (Aleve), and celecoxib (Celebrex) are as safe for patients with inflammatory bowel diseases (IBD) as for people without IBD, according to several 2006 studies. The studies found that NSAIDs may provide pain relief and prevent symptom relapse. Still, patients with IBD should always discuss NSAID use with their doctors.
MMR Vaccine and Crohn’s Disease
The measles, mumps, and rubella (MMR) vaccine does not cause Crohn’s disease or ulcerative colitis, according to a review in the
Cochrane Database
. The report is the most in-depth review of the vaccine to date.
Complications
According to recent studies in
Gastroenterology
:
-
Asthma is the most common accompanying condition among patients with Crohn’s disease. Patients with Crohn’s and ulcerative colitis also have a higher risk for developing arthritis, bronchitis, psoriasis, and pericarditis.
-
The risk for small bowel cancer (a rare type of cancer) is greatly increased among patients with Crohn’s disease, and colorectal cancer risk is slightly increased.
-
Patients with IBD have a greater risk for developing multiple sclerosis and other disease that attack myelin (the fatty sheath that covers nerves).
Diet
Crohn’s disease, and some medications used to treat it, can cause low bone density and bone loss. According to a 2005 study, however, patients with Crohn’s disease may not need to take osteoporosis drugs. Calcium and vitamin D supplements may be adequate.
Investigational Drugs
Several biologic drugs are showing promising results in clinical trials for Crohn’s disease. Some of these drugs have already been approved to treat other inflammatory or autoimmune conditions:
-
Natalizumab (Tysabri)
-
Certolizumab (Cimzia)
-
Sargramostim (Leukine)
-
Fontolizumab (HuZAF)
-
Review Date: 3/6/2007
-
Reviewed By: A.D.A.M. Editorial Team: Greg Juhn, M.T.P.W., David R. Eltz, Kelli A. Stacy. Previously approved by Harvey Simon, MD, Editor-in-Chief, Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital (8/21/2006).
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's
accreditation program
is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s
editorial process
. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
|
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007
A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
